Drug Trial Radar · NCT00229021
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
Last checked: Nov 20, 2026Latest source record: Jun 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
741
Actual
Start
Dec 2003
Primary completion
Not stated
Study completion Mar 2006
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Peninsula Pharmaceuticals, Inc.
- First posted
- Sep 29, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the microbiological cure rate of doripenem versus a comparator antibiotic in the treatment of patients with complicated urinary tract infection or pyelonephritis. The study will also characterize the safety and tolerability of treatment with doripenem in patients with complicated urinary tract infection or pyelonephritis.
Conditions
- Urinary Tract Infections
- Pyelonephritis
Interventions
doripenumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Microbiological response measured at test of cure visit at early follow-up.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.